CBDNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM), BayMedica Collaborate to Build Leading Rare Cannabinoid Company
InMed Pharmaceuticals (NASDAQ: INM) is a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids. The company is creating a pipeline of drug candidates to treat various diseases with high unmet medical needs. “In a move to grow its market presence and strengthen its operations, the company announced that it had entered into a non-binding letter of intent (“LOI”) to acquire BayMedica Inc.,” reads a recent article. “This announcement followed the two parties’ reciprocal research collaboration agreement back in November 2020, which saw them collaborate on several projects since. The agreement allowed BayMedica to assess…